Helex Bio
Bengaluru, India· Est.
Helex Bio builds kidney‑targeted, non‑viral gene‑editing therapies using lipid nanoparticles and AI‑driven drug design.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $3.5M
AI Company Overview
Helex Bio builds kidney‑targeted, non‑viral gene‑editing therapies using lipid nanoparticles and AI‑driven drug design.
Kidney diseaseGenetic disease
Technology Platform
Proprietary kidney‑targeted lipid nanoparticle delivery combined with the Epic‑Cure™ AI‑driven guide‑RNA design platform for precise, non‑viral gene editing.
Opportunities
Expansion of the kidney‑targeted LNP platform to other genetic renal disorders and potential strategic alliances with pharma companies seeking non‑viral gene‑editing solutions.
Risk Factors
Technical challenges in achieving durable in‑vivo editing safety, regulatory uncertainties for CRISPR‑based therapies, and competition from viral‑vector and other non‑viral platforms.
Competitive Landscape
Key competitors include companies developing viral‑vector CRISPR therapies and other LNP‑based gene‑editing platforms; Helex differentiates itself through renal tropism and AI‑driven safety profiling.